BACKGROUND: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10-40 %, although its prognostic relevance remains to be elucidated. METHODS: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2-), luminal/HER2 (HR+ and HER2+), HER2 (HR- and HER2+), or triple negative (HR- and HER2-). RESULTS: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051). CONCLUSIONS: Discordance in receptor status between primary and recurrent breast cancers were seen in 10-30 %. A gain in HR status was significantly associated with better prognosis.
BACKGROUND: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10-40 %, although its prognostic relevance remains to be elucidated. METHODS: Fifty-five breast cancerpatients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2-), luminal/HER2 (HR+ and HER2+), HER2 (HR- and HER2+), or triple negative (HR- and HER2-). RESULTS: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2 %, respectively. Overall, 14 patients (25.5 %) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5 months, p = 0.037, PgR: 141.0 vs. 24.4 months, p = 0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4 months, p = 0.051). CONCLUSIONS: Discordance in receptor status between primary and recurrent breast cancers were seen in 10-30 %. A gain in HR status was significantly associated with better prognosis.
Authors: Ulla Wilking; Eva Karlsson; Lambert Skoog; Thomas Hatschek; Elisabet Lidbrink; Goran Elmberger; Hemming Johansson; Linda Lindström; Jonas Bergh Journal: Breast Cancer Res Treat Date: 2010-07-14 Impact factor: 4.872
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: C Liedtke; K Broglio; S Moulder; L Hsu; S-W Kau; W F Symmans; C Albarracin; F Meric-Bernstam; W Woodward; R L Theriault; L Kiesel; G N Hortobagyi; L Pusztai; A M Gonzalez-Angulo Journal: Ann Oncol Date: 2009-07-12 Impact factor: 32.976
Authors: Julie M Wu; Mary Jo Fackler; Marc K Halushka; Diana W Molavi; M Evangeline Taylor; Wei Wen Teo; Constance Griffin; John Fetting; Nancy E Davidson; Angelo M De Marzo; Jessica L Hicks; Dhananjay Chitale; Marc Ladanyi; Saraswati Sukumar; Pedram Argani Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Elizabeth A Mittendorf; Yun Wu; Maurizio Scaltriti; Funda Meric-Bernstam; Kelly K Hunt; Shaheenah Dawood; Francisco J Esteva; Aman U Buzdar; Huiqin Chen; Sameena Eksambi; Gabriel N Hortobagyi; Jose Baselga; Ana M Gonzalez-Angulo Journal: Clin Cancer Res Date: 2009-11-17 Impact factor: 12.531